Nicotine and amyloid formation.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Biological Psychiatry

• Publication date

  2001-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0006-3223(00)01111-2PMID 11230876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A CRITICAL APPRAISAL

  2002cited by this paper
• Alzheimer's Disease and Related Disorders. Etiology, Pathogenesis, and Therapeutics

  2000cited by this paper
• beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.

  2000cited by this paper
• β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity

  2000cited by this paper
• Prospects for pharmacological intervention in Alzheimer disease.

  2000cited by this paper
• Structural studies of soluble oligomers of the alzheimer β-amyloid peptide

  2000cited by this paper
• The origins of Alzheimer disease: a is for amyloid.

  2000cited by this paper
• Do inhibitors of β-amyloid aggregation also inhibit the aggregation of other amyloid-forming peptides?

  2000cited by this paper
• Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide.

  2000cited by this paper
• High-throughput nuclear magnetic resonance-based screening.

  1999cited by this paper
• Amyloid, prions, and other protein aggregates

  1999cited by this paper
• Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity.

  1999cited by this paper
• Translating cell biology into therapeutic advances in Alzheimer's disease

  1999cited by this paper
• The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

  1999cited by this paper
• Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease.

  1999cited by this paper
• High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease.

  1999influential reference
• Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression

  1999cited by this paper
• Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity.

  1998cited by this paper
• Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

  1998cited by this paper
• Solution Structures of Micelle-bound Amyloid b-( 1-40 ) and b-( 1-42 ) Peptides of Alzheimer ' s Disease

  1998cited by this paper
• Pharmacology of Nicotine

  1998cited by this paper
• Aging renders the brain vulnerable to amyloid β-protein neurotoxicity

  1998cited by this paper
• Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is?

  1998cited by this paper
• Solution Structure Model of Residues 1−28 of the Amyloid β-Peptide When Bound to Micelles

  1998cited by this paper
• Structural analysis of Alzheimer's beta(1-40) amyloid: protofilament assembly of tubular fibrils.

  1998cited by this paper
• Structural and kinetic features of amyloid beta-protein fibrillogenesis.

  1998cited by this paper
• Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes.

  1997cited by this paper
• Soluble Amyloid Aβ-(1–40) Exists as a Stable Dimer at Low Concentrations*

  1997cited by this paper
• Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity.

  1997cited by this paper
• Nicotine modulates the neurotoxic effect of β‐amyloid protein(25–35) in hippocampal cultures

  1997cited by this paper
• Amyloid, the presenilins and Alzheimer's disease.

  1997influential reference
• Fibrillogenesis of Alzheimer Abeta peptides studied by fluorescence energy transfer.

  1997cited by this paper
• Smoking and oestrogen-replacement therapy as protective factors for Alzheimer's disease.

  1997cited by this paper
• Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal.

  1997cited by this paper
• Nicotinic receptor stimulation protects neurons against β‐amyloid toxicity

  1997cited by this paper
• Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β-peptide

  1997cited by this paper
• Discovering High-Affinity Ligands for Proteins

  1997cited by this paper
• Nicotine inhibits amyloid formation by the beta-peptide.

  1996influential reference
• Discovering High-Affinity Ligands for Proteins: SAR by NMR

  1996influential reference
• Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells.

  1996cited by this paper
• In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics.

  1996cited by this paper
• Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease*

  1996cited by this paper
• Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma*

  1996cited by this paper
• Pharmacology of nicotine: addiction and therapeutics.

  1996cited by this paper
• Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution.

  1995cited by this paper
• The toxicity in vitro of beta-amyloid protein.

  1995cited by this paper
• Soluble multimeric Alzheimer β(1–40) pre-amyloid complexes in dilute solution

  1995cited by this paper
• Evidence that Aβ42 is the real culprit in alzheimer's disease

  1995cited by this paper
• 1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence.

  1995cited by this paper
• Structure‐Activity Analyses of β‐Amyloid Peptides: Contributions of the β25–35 Region to Aggregation and Neurotoxicity

  1995cited by this paper
• Evidence that A beta 42 is the real culprit in Alzheimer's disease.

  1995cited by this paper
• Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity.

  1995cited by this paper
• Pulsed field gradient multi-dimensional NMR methods for the study of protein structure and dynamics in solution.

  1995cited by this paper
• Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro.

  1994cited by this paper
• Solution structure of residues 1-28 of the amyloid beta-peptide.

  1994cited by this paper
• Methods to study membrane protein structure in solution.

  1994cited by this paper
• Transthyretin sequesters amyloid beta protein and prevents amyloid formation.

  1994cited by this paper
• Epidemiology and neurobiology of the multiple determinants of Alzheimer's disease.

  1994cited by this paper
• Methodological advances in protein NMR

  1993cited by this paper
• Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein.

  1992cited by this paper
• In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity ☆

  1991cited by this paper
• Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease

  1991cited by this paper
• Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease.

  1991cited by this paper
• Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition.

  1991cited by this paper
• In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity.

  1991cited by this paper
• Advances in Neuro‐oncology

  1990cited by this paper

• Cumulative burden of lifestyle risk factors on Alzheimer's disease in older Korean adults: A nationwide retrospective cohort study

  2025cites this paper
• The Cognitive Changes Among Patients over 65 Years of Age in a Rural Area—The Preliminary Report of Protective and Predisposing Factors

  2025cites this paper
• Plant-Based Inhibitors of Protein Aggregation

  2025cites this paper
• Nicotinic acetylcholine receptor activation induces BACE1 transcription via the phosphorylation and stabilization of nuclear SP1.

  2023cites this paper
• Inhibition of Amyloid β Aggregation and Cytotoxicity by Berbamine Hydrochloride.

  2023cites this paper
• Therapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment

  2022cites this paper
• Beyond the Obvious: Smoking and Respiratory Infection Implications on Alzheimer's Disease.

  2020cites this paper
• Non-polyphenolic natural inhibitors of amyloid aggregation.

  2020cites this paper
• Astrocytic α7 Nicotinic Receptor Activation Inhibits Amyloid-β Aggregation by Upregulating Endogenous αB-crystallin through the PI3K/Akt Signaling Pathway.

  2018cites this paper
• Alzheimer’s Disease in Systemic Sclerosis Patients: A Nationwide Population-Based Cohort Study

  2018cites this paper
• Effect of smoking cessation on the risk of dementia: a longitudinal study

  2018cites this paper
• Alzheimer’s disease and cigarette smoke components: effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-β peptide aggregation

  2017cites this paper
• Nicotine mediates expression of genes related to antioxidant capacity and oxidative stress response in HIV-1 transgenic rat brain

  2016cites this paper
• The discovery of a novel series of amyloid-β antiaggregants based on the structure of 3-hydroxyanthranilic acid: a detailed analysis of the mechanism of action underpinning antiaggregant activity

  2015cites this paper
• World Alzheimer report 2014: Dementia and risk reduction

  2015cites this paper
• Perspectives on Inhibiting β‐Amyloid Aggregation through Structure‐Based Drug Design

  2015cites this paper
• Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease

  2015cites this paper
• Nicotine mediates oxidative stress and apoptosis through cross talk between NOX1 and Bcl-2 in lung epithelial cells.

  2014cites this paper
• Therapeutic Interventions for the Suppression of Alzheimer's Disease: Quest for a Remedy.

  2014cites this paper
• The role of Hsp20 in Alzheimer's disease

  2014cites this paper
• World Alzheimer Report 2014: Dementia and risk reduction: An analysis of protective and modifiable risk factors

  2014cites this paper
• Targeted studies on the interaction of nicotine and morin molecules with amyloid β-protein

  2014cites this paper
• Prevention of Brain Disorders by Nicotine

  2013cites this paper
• The Effects of Acute Nicotine Administration on Memory Formation and Neural Activity in the Hippocampus, Perirhinal Cortex, and Medial Septum: Implications for Neurodegenerative Disorders

  2013cites this paper
• The influence of inhibiting or stimulating the expression of the α3 subunit of the nicotinic receptor in SH-SY5Y cells on levels of amyloid-β peptide and β-secretase.

  2013cites this paper
• The effects of chronic calcium dysregulation on behavioral and pathological features of Alzheimer's disease

  2013cites this paper
• Strategies for Inhibiting Protein Aggregation: Therapeutic Approaches to Protein-Aggregation Diseases

  2012cites this paper
• Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimer's disease.

  2011cites this paper
• Chronic Stress and Alzheimer’s Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine

  2011cites this paper
• α7 Nicotinic receptor activation reduces β‐amyloid‐induced apoptosis by inhibiting caspase‐independent death through phosphatidylinositol 3‐kinase signaling

  2011cites this paper
• Surface Plasmon Resonance Based Biosensors for Exploring the Influence of Alkaloids on Aggregation of Amyloid-β Peptide

  2011cites this paper
• A Cyclic Undecamer Peptide Mimics a Turn in Folded Alzheimer Amyloid β and Elicits Antibodies against Oligomeric and Fibrillar Amyloid and Plaques

  2011cites this paper
• Nicotine Reduces the Cytotoxic Effect of Glycated Proteins on Microglial Cells

  2010cites this paper
• Midlife Smoking, Apolipoprotein E and Risk of Dementia and Alzheimer’s Disease: A Population-Based Cardiovascular Risk Factors, Aging and Dementia Study

  2010cites this paper
• Donepezil and galanin interactions in an animal model of Alzheimer’s disease

  2010cites this paper
• Association constants of pyridine and piperidine alkaloids to amyloid beta peptide determined by electrochemical impedance spectroscopy.

  2010cites this paper
• Structurally distinct toxicity inhibitors bind at common loci on β‐amyloid fibril

  2010cites this paper
• Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease?

  2010cites this paper
• Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease.

  2010cites this paper
• Role of vascular risk factors and vascular dysfunction in Alzheimer's disease.

  2010cites this paper
• Association Constants of Pyridine and Piperidine Alkaloids to Amyloid ß Peptide Determined by Electrochemical Impedance Spectroscopy

  2010cites this paper
• The Polyphenol Piceid Destabilizes Preformed Amyloid Fibrils and Oligomers In Vitro: Hypothesis on Possible Molecular Mechanisms

  2009cites this paper
• Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology.

  2009cites this paper
• Computational insights into the development of novel therapeutic strategies for Alzheimer's disease.

  2009cites this paper
• Role of Environmental and Inflammatory Toxicity in Neuronal Cell Death

  2008cites this paper
• Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies.

  2008cites this paper
• Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer’s ß-amyloid fibrils in vitro

  2007cites this paper
• Electrochemical impedance spectroscopy for study of amyloid beta-peptide interactions with (-) nicotine ditartrate and (-) cotinine.

  2007cites this paper
• The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure.

  2007cites this paper
• Small molecule inhibitors of Abeta assembly

  2007cites this paper
• Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases.

  2007cites this paper
• Alzheimer’s Disease: Halothane Induces Aβ Peptide to Oligomeric Form—Solution NMR Studies

  2006cites this paper
• Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro.

  2006cites this paper
• The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta.

  2006cites this paper
• Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease.

  2006cites this paper
• Acetylcholine receptors and tau phosphorylation.

  2006cites this paper
• Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro.

  2006cites this paper
• Alzheimer’s Disease: Halothane Induces Aβ Peptide to Oligomeric Form—Solution NMR Studies

  2006cites this paper
• Nicotine attenuates the β‐amyloid neurotoxicity through regulating metal homeostasis

  2006cites this paper
• Antioxidant compounds have potent anti‐fibrillogenic and fibril‐destabilizing effects for α‐synuclein fibrils in vitro

  2006cites this paper
• A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

  2005cites this paper
• Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro.

  2005cites this paper
• Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro.

  2005cites this paper
• Preformed β-amyloid fibrils are destabilized by coenzyme Q10 in vitro

  2005cites this paper
• Ferulic acid destabilizes preformed β-amyloid fibrils in vitro

  2005cites this paper
• Effects of Nicotine in Models of Alzheimer's Disease

  2005cites this paper
• Attenuation of Aβ deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking

  2005cites this paper
• Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro.

  2005cites this paper
• Rationale and prospects for drugs that target nicotinic acetylcholine receptors

  2004cites this paper
• Nicotine attenuates β‐amyloid peptide‐induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures

  2004cites this paper
• Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro.

  2004cites this paper
• Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease".

  2004cites this paper
• Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro.

  2004cites this paper
• Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro

  2004cites this paper
• Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients.

  2004cites this paper
• Both the D-(+) and L-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity.

  2004cites this paper
• Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients

  2004cites this paper
• Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease

  2003cites this paper
• Alzheimer's Disease: Search for Therapeutics

  2003cites this paper
• Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells.

  2003cites this paper
• Nicotinic receptors and Alzheimer's disease

  2003cites this paper
• Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease.

  2003cites this paper
• Glycation of the amyloid β-protein by a nicotine metabolite: A fortuitous chemical dynamic between smoking and Alzheimer's disease

  2003cites this paper
• Glutamate and Amyloid β-Protein Rapidly Inhibit Fast Axonal Transport in Cultured Rat Hippocampal Neurons by Different Mechanisms

  2003cites this paper
• The Role of Aβ-Peptide on Spatial Memory, EEG, Auditory Evoked Potentials And Nicotinic Cholinergic Receptors in A/P Transgenic Mice

  2003cites this paper
• Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins.

  2002cites this paper
• Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro.

  2002cites this paper
• Egg yolk platelet proteins from Xenopus laevis are amyloidogenic.

  2002cites this paper
• Chronic nicotine treatment reduces β‐amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw)

  2002cites this paper
• Nicotine Reduces the Secretion of Alzheimer's β‐Amyloid Precursor Protein Containing β‐Amyloid Peptide in the Rat without Altering Synaptic Proteins

  2002cites this paper